AGALIMMUNE LTD.
🇬🇧United Kingdom
Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour
Phase 1
Completed
- Conditions
- Superficial, Palpable, Unresectable/Metastatic Solid Tumour
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Agalimmune Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03593226
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸AHS Hospital Corp., Morristown, New Jersey, United States
🇺🇸Providence Cancer Institute Franz Clinic, Portland, Oregon, United States
News
No news found